The Company applies its thermodynamic, computational discovery platform—ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer's disease and ALS.

ProMIS Neurosciences is working to detect, target and treat the root causes of neurodegenerative diseases affecting millions of families globally


Precision Medicine
By targeting the right drug to the right patient by using both a diagnostic and a therapeutic together – has had dramatic positive impact in a number of diseases. It appears to be important in Alzheimer’s and neurodegenerative disease as well.
As its primary objective, the Company will focus on the discovery and development of precision therapeutics directed against several strains of misfolded, neurotoxic prion forms of Amyloid beta (Aβ), the root cause of Alzheimer’s.

Scientific Foundation
Is centered on the growing consensus that prion forms of misfolded proteins are key drivers of neurodegenerative diseases. Prion forms of misfolded proteins are characterized by their neurotoxicity and ability to progressively spread throughout the brain, killing neurons. Numerous neurodegenerative diseases exhibit toxic, prion-like protein misfolding, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). Recent published evidence indicates that for a given misfolded protein there exist multiple prion-like strains, each strain representing a target against which specific therapeutics can be developed. ProMIS has identified distinct targets on strains of misfolded SOD1 in ALS and on misfolded strains of Amyloid beta in AD.

Core Science & Technology
 ,Neil Cashman has been among the leaders in the field of misfolded proteins (with over 300 publications and over 10,000 citations and 45 patent applications), and is one of several leading researchers of strain specific protein misfolding.

Intellectual Property
ProMIS Neurosciences, Inc. utilizes two proprietary computational discovery technologies, ProMIS™ and Collective Coordinates, to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. ProMIS™ Neurosciences has a broad patent estate granted relating to misfolded SOD1 in ALS and multiple patents submitted for disease specific epitopes (targets) on misfolded Amyloid beta in AD.

Harnessing the Power of Precision Medicine




Massive market opportunity & unmet medical need

No therapies available today to stop progression of Alzheimer’s disease (AD). Total US AD healthcare costs > $500BB, expected to triple over next 10-15 years. ProMIS products are uniquely designed to block the toxic strains of Amyloid beta, to stop the fundamental, underlying driver causing death of brain neurons in AD.

Management team

Experienced, complementary management team with outstanding scientific and business advisory boards.

Significant risk mitigation/reduction of ProMIS proposed products

Big pharma spent $BB on failed, or partially successful clinical trials. Results of these trials clearly indicate the ideal target product profile, i.e., to succeed, products must target the toxic prion form of Amyloid beta, and not target the other forms of Amyloid beta.

ProMIS products are designed to target uniquely these toxic strains of Amyloid beta.


  • Exchange & Symbol:                   TSX: PMN
  • Issued and Outstanding:         170,363,473
  • Fully Diluted:                                  201,469,914
  • Auditor:                                             PricewaterhouseCoopers LLP
  • Legal Firm:                                       Bereskin & Parr

Website:        ProMis Neuroscience
Stock Info:


  • All information provided is “as is” for informational and educational purposes only, and not intended for trading or investment advice. 8020 does not advocate the purchase or sale of a security or investment mentioned and recommends any investment advice should be obtained through professional and licensed investment advisors.
  • 8020 Connect does not screen, audit, evaluate, endorse, recommend or represent a product, service, or the individual companies listed or posted on the 8020 site. Should you decide to purchase any product or service, advocate or invest in a company listed on 8020, you do so at your own risk.
  • The information displayed on the 8020 site should not be construed as an offer to buy, sell, solicit or influence an investment decision by 8020 or its employees, officers, directors or consultants. Any investment or security referred to or learned about on the 8020 site are not suitable for all investors, and investment advice from a licensed investment advisor is highly recommended.
  • It is possible that 8020 and its employees, officers, directors or consultants may have investments in a company listed on the 8020 site.
  • 8020 Connect provides the technology platform for 8020 connect members on an “as is” and “as available” basis. 8020 Connect does not provide any express warranties or representations to the full extent permissible under the applicable law.
  • 8020 Connect does not have an obligation to monitor user activity and therefore disclaims all liability for identity theft or other misuse of your identity or information.
  • 8020 Connect does not guarantee that its services will function without interruption or errors during its service whether from external factors, internal maintenance, user issues, or any other reason. 8020 Connect disclaims all liability for damages or loss of income due to the above interruptions, errors or issues.
Eugene Williams is a former SVP at Genzyme, with senior roles integrating commercialization, drug development, and deal making. He is also an entrepreneur, as the founder and director of Adheris, which became the largest company in the patient adherence area. He was previously a strategy consultant at Bain and Corporate Decisions Inc. (a Bain Spin off, now part of Oliver Wyman), where he was co-Head of Healthcare and spent extensive time on speeding and improving the drug development process and on commercialization strategies. Mr. Williams was most recently the CEO of Dart Therapeutics, an Orphan Disease drug development company. Mr. Williams holds a B.A. from Harvard University and an M.B.A. from Harvard Business School.
Elliot Goldstein brings a unique track record in the clinical, regulatory and commercial development of new pharmaceuticals. Dr. Goldstein began his career with Sandoz Pharmaceuticals (now Novartis), a fourteen-year period on drug development in France, Basel, Switzerland Global Headquarters, including as Head of Clinical R&D in the United States. He subsequently held positions as SVP of Strategic Product Development at SmithKline Beecham (now GSK), CEO of British Biotech (Oxford, UK), Chief Operating Officer and Chief Medical Officer of Maxygen, and President and CMO of a startup biotech devoted to development of biosimilar monoclonal antibodies. Dr. Goldstein holds an M.D. from the University Aix-Marseille II, Marseille, France, and a B.Sc. from McGill University, Montreal.
Dr. Cashman is a physician and scientist focused on neurodegenerative diseases. His first academic posting was at Montreal Neurological Institute and Hospital of McGill University. From 1998 to 2005, he was the Diener Professor of Neurodegenerative Diseases at the University of Toronto. In 2005, Professor Cashman moved to the University of British Columbia, where he holds the Canada Research Chair in Neurodegeneration and Protein Misfolding Diseases, and serves as the Director of the UBC ALS Centre. He has procured over $50 million in research grant funding from the CIHR, CRC, NCE, NIH, and various corporations for his work involving protein misfolding and prion technologies. He was awarded the Jonas Salk Prize for biomedical research in 2000, and was elected a Fellow of the Canadian Academy of Health Sciences in 2008. He is recognized worldwide as one of the leading research scientists pioneering the emerging fields of prion biology and protein misfolding diseases, in particular Alzheimer’s disease and amyotrophic lateral sclerosis (ALS).
Prof. Steven Plotkin is a theoretical and computational biophysicist whose research focuses on protein folding and misfolding in neurodegenerative disease, protein evolution and cellular differentiation, and the molecular mechanisms of cancer. He has been a professor at UBC in the Department of Physics and Astronomy since 2001, where he was appointed as the Canada Research Chair in Theoretical Molecular Biophysics. He was an Alfred P. Sloan Research Fellow in 2005-2006, a Killam Faculty Research Fellow in 2010, and is now an associate member of the Genome Sciences and Technology Program, the Bioinformatics Program, and the Institute for Applied Mathematics at the University of British Columbia. Several of his publications have received the Faculty of 1000 designation, placing them in the top 2% of published articles in biology and medicine.
Plotkin is recognized internationally for his fundamental contributions to the energy landscape theory of protein folding, and presents his research findings in protein misfolding and neurodegeneration, and protein geometry and disorder as an invited speaker at several annual conferences and symposia. His research is currently supported by grants from CIHR, NSERC, APRI, ALS-Canada, and Compute Canada.
Janet Clennett is a Chartered Professional Accountant (CPA, CA) who has held several senior financial management positions in emerging biotechnology firms. Ms. Clennett first joined the Company as Director of Finance in November of 2007. During her 7 year tenure she held the positions of Acting CFO, and subsequently CFO from September 2010 to January 2013. Prior to that, she worked as Controller, then CFO of Fralex Therapeutics Inc. (2005-2007) and as Controller of Novadaq Technologies Inc. (2002-2005). Janet earned her CPA, CA while employed at KPMG. Ms. Clennett has an Honours Bachelor of Mathematics degree from the University of Waterloo.
Senior partner at Kirwin LLP, has been advising and representing businesses in a range of industries and sizes from local to multinational for over 30 years. He obtained his B.A. in Economics (First Class Standing) from the University of Alberta in 1978 followed by his J.D. from the University of Toronto, Faculty of law in 1982. He practiced initially with the Canadian Federal Department of Justice from 1982 to 1986 then founded the predecessor to Kirwin LLP where he currently practices in Edmonton Alberta.
William W. Wyman began his career at the management consulting firm Booz Allen and Hamilton. After working for the firm in New York, Duesseldorf Germany, Athens Greece, and Dallas Texas, he returned to New York to become the President of the Management Consulting Group, a member of the executive committee, and a member of the Board of Directors. Subsequently, Mr. Wyman co-founded the management consulting firm, Oliver Wyman & Co. Now part of Marsh & McLennan, the firm employs 3,700 professionals in 26 countries. Mr Wyman has served as director to more than eighteen public and private companies, mostly smaller companies in the technology and finance sectors. He also has served as an advisor to several private equity partnerships. Mr. Wyman received his BA from Colgate University, and his MBA from the Harvard Business School. He also served in the U.S. Navy for four years. He resides in Hanover, NH.
Mr. Roth is the founding director and partner at FiveT Capital Holding AG, a Swiss-based innovative financial holdings firm with activities in quantitative tailored investment and risk management solutions for institutional investors and high net-worth individuals with sophisticated wealth management, investment and risk requirements. He has many years of experience as a CIO and portfolio manager for FiveT Capital AG and as an equity specialist and proprietary trader at Baaderbank AG.

Mr. Roth holds a masters degree in economics from Hohenheim University and is a board member of Insilico Biotechnology AG, a Stuttgart/Germany-based global leader in providing solutions and software for the simulation of living cells

Industry Articles
Early & Younger-Onse...
Alzheimer’s Disease can be a daunting diagnosis, especially if it comes before it typically should. Younger-onset Alzheimer’s affects those under 6...
Read More
Day-to-Day Living wi...
Caring for someone with Alzheimer’s or Dementia can be a rewarding job, whether you’re a hired care-giver or a loved one taking care of another lov...
Read More
Stages of Alzheimer’...
There are three main stages of Alzheimer’s Disease, and while the disease affects each individual in a unique way, the disease can be categorized i...
Read More
History of Alzheimer's
Today, Alzheimer’s is a leading cause of death and over 560,000 Canadians are living with dementia as of 2016. This number is expected to rise to o...
Read More